Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L G Qiu

Showing results (31-40 of 62) with videos related to

Pageof 7
Sort By:
Zhonghua Yi Xue Za Zhi|August 15, 2022
[Efficacy and prognosis of newly diagnosed multiple myeloma patients treated with bortezomib, lenalidomide and dexamethasone]J Y Xu, W W Yan, H S Fan, et al.
Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi|January 20, 2022
[Immunoglobulin M multiple myeloma: a six-case report and literature review]W W Yan, H S Fan, J Y Xu, et al.
Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi|November 23, 2017
[Multiple myeloma associated with myeloid tumor: 5 cases report and literatures review]B Jiang, J Y Qi, Y Xu, et al.
Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi|January 28, 2023
[Clinical and biological characteristics of non-IgM lymphoplasmacytic lymphoma]Y Yu, W J Xiong, J W Chen, et al.
Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi|August 7, 2023
[Clinical characteristics of 11 patients with chronic lymphocytic leukemia with t (14;19) (q32;q13)]C H Cui, Y N Chang, J Zhou, et al.
Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi|August 15, 2022
[Large B-cell lymphoma with IRF4 rearrangement: six case reports and a literature review]Y Yu, Q Sun, C W Li, et al.
Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi|October 7, 2023
[Safety and feasibility of 120 min rapid infusion regimen of daratumumab in patients with multiple myeloma]T H Wang, R Hao, B N Xu, et al.
Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi|October 7, 2023
[A prospective clinical trial of TCD-induced regimen for symptomatic Waldenström macroglobulinemia]Y S Huang, W J Xiong, Y Yu, et al.
Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi|June 28, 2017
[Dose-adjusted EPOCH/EDOCH plus rituximab in untreated double-protein expression lymphoma]W Liu, J Li, W Y Huang, et al.
Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi|January 25, 2018
[Clinical and bacteriological analysis of lymphoid tissue neoplasms patients with bacteria bloodstream infections]T Y Wang, Z J Li, Q S Lin, et al.
Pageof 7

Showing results (31-40 of 62) with videos related to

Sort By:
Pageof 7
Zhonghua Yi Xue Za Zhi|August 15, 2022
[Efficacy and prognosis of newly diagnosed multiple myeloma patients treated with bortezomib, lenalidomide and dexamethasone]J Y Xu, W W Yan, H S Fan, et al.
Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi|January 20, 2022
[Immunoglobulin M multiple myeloma: a six-case report and literature review]W W Yan, H S Fan, J Y Xu, et al.
Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi|November 23, 2017
[Multiple myeloma associated with myeloid tumor: 5 cases report and literatures review]B Jiang, J Y Qi, Y Xu, et al.
Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi|January 28, 2023
[Clinical and biological characteristics of non-IgM lymphoplasmacytic lymphoma]Y Yu, W J Xiong, J W Chen, et al.
Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi|August 7, 2023
[Clinical characteristics of 11 patients with chronic lymphocytic leukemia with t (14;19) (q32;q13)]C H Cui, Y N Chang, J Zhou, et al.
Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi|August 15, 2022
[Large B-cell lymphoma with IRF4 rearrangement: six case reports and a literature review]Y Yu, Q Sun, C W Li, et al.
Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi|October 7, 2023
[Safety and feasibility of 120 min rapid infusion regimen of daratumumab in patients with multiple myeloma]T H Wang, R Hao, B N Xu, et al.
Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi|October 7, 2023
[A prospective clinical trial of TCD-induced regimen for symptomatic Waldenström macroglobulinemia]Y S Huang, W J Xiong, Y Yu, et al.
Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi|June 28, 2017
[Dose-adjusted EPOCH/EDOCH plus rituximab in untreated double-protein expression lymphoma]W Liu, J Li, W Y Huang, et al.
Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi|January 25, 2018
[Clinical and bacteriological analysis of lymphoid tissue neoplasms patients with bacteria bloodstream infections]T Y Wang, Z J Li, Q S Lin, et al.
Pageof 7